





FUND PHILOSOPHY*

large cap stocks

The fund aims to generate steady returns by investing in the leading stocks of the chosen sectors, predominantly amongst the large cap universe. The portfolio approach is based on a robust three pillar strategy, namely:

Large Cap Fund - An open ended equity scheme predominantly investing in

Buying the right sectors – Identifying and investing in the right sectors with the flexibility to have large deviations from the benchmark sector weights.

IDFC LARGE CAP FUND

Buying the sector leaders - Investing in the sector leader companies having strong fundamentals, solid execution track record as well as resilient balance sheet to withstand any cyclical downturns.

Tactical allocation to mid/small caps – Opportunistic allocation to take advantage of any mispriced opportunities or a benevolent risk-on environment.

The fund has a "Growth" and "Quality" oriented investment style, and is focused on companies having a strong visibility of earnings growth coupled with healthy return on capital employed.

FUND FEATURES:

(Data as on 30th November'22)

Category: Large Cap

Monthly Avg AUM: ₹ 1,114.60 Crores Inception Date: 9th June 2006

Fund Manager: Mr. Sumit Agrawal & Mr. Sachin Relekar (w.e.f. 1st March 2022)

Other Parameters:

Beta: 0.88 **R Squared:** 0.95

Standard Deviation (Annualized): 20.04%

Benchmark: S&P BSE 100 TRI

(w.e.f. 18/04/2017)

Minimum Investment Amount: ₹5,000/-and any amount thereafter.

Exit Load:

- If redeemed/switched out within 365 days from the date of allotment:
 - > Up to 10% of investment: Nil,
 - > For remaining investment: 1% of applicable NAV
- If redeemed / switched out after 365 days from date of allotment: Nil. (w.e.f. 25th June 2021)

Sip Dates : (Monthly/Quarterly*) Investor may choose any day of the month except 29th, 30th & 31st of instalment. *Any day of next month from the Quarter end.

Options Available: Growth, IDCW[®] (Payout, Reinvestment and Sweep (from Equity Schemes to Debt Schemes only))

PLAN	IDCW® RECORD DATE	₹/UNIT	NAV
REGULAR	22-Jul-21	0.89	17.8600
	16-Mar-20	1.04	12.1800
	19-Mar-19	0.77	15.1200
DIRECT	22-Jul-21	1.11	22.3200
	16-Mar-20	1.27	14.9900
	19-Mar-19	0.95	18.4400

Face Value per Unit (in ₹) is 10

Income Distribution cum capital withdrawal is not guaranteed and past performance may or may not be sustained in future. Pursuant to payment of Income Distribution cum capital withdrawal, the NAV of the scheme would fall to the extent of payout and statutory levy (as applicable).

®Income Distribution cum capital withdrawal

OUTLOOK

How has been the November for Equity markets?

Global equities strengthened across regions (+7.6% MoM/-16.4% YTD). Brazil was the only outlier while all other regions improved (US surging 5%/China +30%/Euro area up 11%).

Indian equities (MSCI India) gained (USD terms, +5% MoM/-3% YTD), while underperforming the region and its peers (MSCI APxJ/EM: -17%/+15% MoM). Performance of both mid-caps (up ~2% MoM) and small caps (up ~3% MoM) was positive, though weaker than large caps (up ~4% MoM). All sectors barring Consumer Discretionary, Auto and Utilities ended the month in the green as NIFTY improved (up ~4% MoM), clocking a new lifetime high of 18,758 at the close of the month. INR appreciated by 1.7% MoM, reaching ~81.43/USD in November. DXY (Dollar Index) weakened 5% over the month, closing the month at 105.95 (from 111.53 a year earlier).

After the exhilarating moves in CY 20 and CY 21, market movement during CY 22 has been more sedate. Nifty50 till a few weeks back was flirting with negative return on a calendar year basis. Clearly, equity returns have been underwhelming. Yet, the markets have climbed the proverbial "walls of worry" to cross the previous peak touched in Oct'21.

Is the Indian market overvalued, as a result becomes a difficult question to answer. "Are we in bubble territory" would be a relatively easier question to answer – No. A simple, yet effective test of the market valuation would be to compare Small Cap Index earnings to Nifty50. In CY 17, Small cap index traded at a premium to Nifty and needed a trigger to unravel. Thankfully, in the market rally since Apr'2020, Small cap index has never traded at a premium to Nifty. Thus, while valuations may be elevated we are not in bubble territory.

This should be the most important take away for investors, moderate return expectations not equity allocation at the current juncture...this train can chug along for some more time.

Arpit Kapoor managed this scheme up to 28th February 2022

Ratios calculated on the basis of 3 years history of monthly data.

The above mentioned is the current strategy of the Fund Manager. However, asset allocation and investment strategy shall be within broad

PORTFOLIO (30 November 2022)

	D	F	C
IDFC	MUT	UAL	FUND

Name of the Instrument	% to NAV	Name of the Instrument	% to NAV
Equity and Equity related Instruments 96.92%		Dr. Reddy's Laboratories	0.96%
Banks	35.32%	Cipla	0.94%
HDFC Bank	9.92%	Divi's Laboratories	0.91%
ICICI Bank	9.81%	Construction	3.14%
State Bank of India	7.80%	Larsen & Toubro	2.42%
Axis Bank	3.03%	PSP Projects	0.72%
Kotak Mahindra Bank	2.78%	Finance	3.09%
IndusInd Bank	1.98%	Cholamandalam Invt and Fin Co	1.59%
IT - Software	12.61%	Bajaj Finance	1.50%
Infosys	6.43%	Telecom - Services	2.02%
Larsen & Toubro Infotech	3.04%	Bharti Airtel	2.02%
Tata Consultancy Services	2.66%	Leisure Services	1.84%
MphasiS	0.47%	Jubilant Foodworks	1.84%
Diversified FMCG	6.30%	IT - Services	1.40%
ITC	3.79%	L&T Technology Services	1.40%
Hindustan Unilever	2.51%	Electrical Equipment	1.37%
Petroleum Products	6.30%	ABB India	1.37%
Reliance Industries	6.30%	Realty	1.14%
Automobiles	5.95%	Sunteck Realty	1.14%
Maruti Suzuki India	3.23%	Personal Products	1.07%
Mahindra & Mahindra	1.50%	Godrej Consumer Products	1.07%
TVS Motor Company	1.22%	Cement & Cement Products	1.04%
Consumer Durables	4.39%	UltraTech Cement	1.04%
Asian Paints	1.67%	Industrial Products	1.03%
Kajaria Ceramics	1.36%	Bharat Forge	1.03%
Titan Company	1.35%	Insurance	0.61%
Chemicals & Petrochemicals	4.33%	SBI Life Insurance Company	0.61%
Anupam Rasayan India	2.34%	Corporate Bond	0.003%
Rossari Biotech	1.99%	Britannia Industries AAA	0.003%
Pharmaceuticals & Biotechnology	3.97%	Net Cash and Cash Equivalent	3.07%
Sun Pharmaceutical Industries	1.17%	Grand Total	100.00%



















